scholarly journals Podocyte injury in focal segmental glomerulosclerosis: Lessons from animal models (a play in five acts)

2008 ◽  
Vol 73 (4) ◽  
pp. 399-406 ◽  
Author(s):  
V.D. D'Agati
2018 ◽  
Vol 293 (52) ◽  
pp. 20227-20239 ◽  
Author(s):  
Shuai Hu ◽  
Runhong Han ◽  
Jingsong Shi ◽  
Xiaodong Zhu ◽  
Weisong Qin ◽  
...  

2013 ◽  
Vol 14 (1) ◽  
Author(s):  
Sylvana ML de Mik ◽  
Martin J Hoogduijn ◽  
Ron W de Bruin ◽  
Frank JMF Dor

2015 ◽  
Vol 185 (8) ◽  
pp. 2118-2131 ◽  
Author(s):  
Satoshi Hara ◽  
Namiko Kobayashi ◽  
Kazuo Sakamoto ◽  
Toshiharu Ueno ◽  
Shun Manabe ◽  
...  

2018 ◽  
Vol 3 (6) ◽  
pp. 1443-1453 ◽  
Author(s):  
Ashish K. Solanki ◽  
Ehtesham Arif ◽  
Thomas Morinelli ◽  
Robert C. Wilson ◽  
Gary Hardiman ◽  
...  

2014 ◽  
Vol 2014 ◽  
pp. 1-11 ◽  
Author(s):  
Crislaine Aparecida da Silva ◽  
Mariana Molinar Mauad Cintra ◽  
Eliângela de Castro Côbo ◽  
Marcos Vinícius da Silva ◽  
Fabiano Bichuette Custódio ◽  
...  

Focal segmental glomerulosclerosis (FSGS) is a glomerulopathy associated with nephrotic syndrome and podocyte injury. FSGS occurs both in children and adults and it is considered the main idiopathic nephrotic syndrome nowadays. It is extremely difficult to establish a morphological diagnosis, since some biopsies lack a considerable quantifiable number of sclerotic glomeruli, given their focal aspect and the fact that FSGS occurs in less than half of the glomeruli. Therefore, many biological molecules have been evaluated as potential markers that would enhance the diagnosis of FSGS. Some of these molecules and receptors are associated with the pathogenesis of FSGS and have potential use in diagnosis.


2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
Elena Torban ◽  
Martin Bitzan ◽  
Paul Goodyer

Focal segmental glomerulosclerosis refers to a set of particular histopathologic lesions in which steroid-resistant podocyte injury leads to patchy adhesions between the glomerular tuft and Bowman's capsule, followed by progressive glomerulosclerosis and proteinuric renal failure. Because of the nonspecific nature of this lesion, it has been difficult to classify the various forms of primary nephrotic syndrome in children. However, with the recognition of hereditary FSGS caused by mutations podocyte slit diaphragm genes, it is increasingly clear that the steroid-resistant form of FSGS that recurs in the renal allografts (R-FSGS) constitutes a distinct clinical entity. Capitalizing on recent studies in which patients have been screened for slit diaphragm gene mutations, this review focuses on the natural history and pathogenesis of R-FSGS.


2021 ◽  
pp. 1-9
Author(s):  
Ke Sun ◽  
Qionghong Xie ◽  
Chuan-Ming Hao

<b><i>Background:</i></b> Focal segmental glomerulosclerosis (FSGS) is a histologic pattern characterized by focal glomerular scarring, which often progresses to systemic and diffuse glomerulosclerosis. Previous studies have emphasized that the initiation of classic FSGS occurs in podocytes. The dysfunction and loss of podocytes have been associated with the development of proteinuria and the progression of various diseases. In addition, primary, secondary, and genetic FSGS are caused by different mechanisms of podocyte injury. <b><i>Summary:</i></b> The potential sources and mechanism of podocyte supplementation are the focus of our current research. Increasing attention has been paid to the role played by parietal epithelial cells (PECs) during the progression of FSGS. PECs are not only the primary influencing factors in glomerulosclerosis lesions but also have repair abilities, which remain a focus of debate. Notably, other resident glomerular cells also play significant roles in the progression of this disease. <b><i>Key Message:</i></b> In this review, we focus on the mechanism of scarring in FSGS and discuss current and potential therapeutic strategies.


2020 ◽  
Vol 134 (7) ◽  
pp. 695-710
Author(s):  
Yingjin Qiao ◽  
Pei Wang ◽  
Mingyang Chang ◽  
Bohan Chen ◽  
Yan Ge ◽  
...  

Abstract The clinical effectiveness of adrenocorticotropin in inducing remission of steroid-resistant nephrotic syndrome points to a steroidogenic-independent anti-proteinuric activity of melanocortins. However, which melanocortin receptors (MCR) convey this beneficial effect and if systemic or podocyte-specific mechanisms are involved remain uncertain. In vivo, wild-type (WT) mice developed heavy proteinuria and kidney dysfunction following Adriamycin insult, concomitant with focal segmental glomerulosclerosis (FSGS) and podocytopathy, marked by loss of podocin and synaptopodin, podocytopenia and extensive foot process effacement on electron microscopy. All these pathologic findings were prominently attenuated by NDP-MSH, a potent non-steroidogenic pan-MCR agonist. Surprisingly, MC1R deficiency in MC1R-null mice barely affected the severity of Adriamycin-elicited injury. Moreover, the beneficial effect of NDP-MSH was completely preserved in MC1R-null mice, suggesting that MC1R is likely non-essential for the protective action. A direct podocyte effect seems to contribute to the beneficial effect of NDP-MSH, because Adriamycin-inflicted cytopathic signs in primary podocytes prepared from WT mice were all mitigated by NDP-MSH, including apoptosis, loss of podocyte markers, de novo expression of the podocyte injury marker desmin, actin cytoskeleton derangement and podocyte hypermotility. Consistent with in vivo findings, the podoprotective activity of NDP-MSH was fully preserved in MC1R-null podocytes. Mechanistically, MC1R expression was predominantly distributed to glomerular endothelial cells in glomeruli but negligibly noted in podocytes in vivo and in vitro, suggesting that MC1R signaling is unlikely involved in direct podocyte protection. Ergo, melanocortin therapy protects against podocyte injury and ameliorates proteinuria and glomerulopathy in experimental FSGS, at least in part, via a podocyte-specific non-MC1R-mediated melanocortinergic signaling.


Sign in / Sign up

Export Citation Format

Share Document